The Law Offices of Frank R. Cruz Continues Its Investigation of Humacyte, Inc. (HUMA) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation on behalf of Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ:HUMA) investors concerning the Company and its officers’ possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

On August 9, 2024, after market hours, Humacyte disclosed that the FDA needed “additional time to complete its review of its Biologic License Application (BLA) for the acellular tissue engineered vessel (ATEV) in the vascular trauma indication,” stating that the FDA had conducted inspections of the Company’s manufacturing facilities and clinical sites and has “actively engaged” with the Company “in multiple discussions regarding [its] BLA filing.”

On this news, Humacyte’s stock price fell $1.29, or 16.4%, to close at $6.62 per share on August 12, 2024, thereby injuring investors.

Then, on October 17, 2024, the FDA revealed that it had identified a number of violations at Humacyte’s North Carolina facility, including “no microbial quality assurance” and “no microbial testing,” and “that quality oversight is inadequate.”

On this news, Humacyte’s stock price fell $0.95, or 16.4%, to close at $4.86 per share on October 17, 2024, thereby injuring investors further.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased Humacyte securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 2121 Avenue of the Stars, Suite 800, Los Angeles, California 90067 at 310-914-5007, by email to [e-mail], or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.